MyoPax

The vanguard in cell and gene therapies for muscle disorders

MyoPax is developing a method for the isolation and cultivation of regenerative muscle stem cells.

This enables MyoPax to produce large high-purity populations of stem cells that they call PHSats: Primary Human Satellite cell derived muscle stem cells.

MyoPax is based in Berlin, Germany/Copenhagen, Denmark and is headed by the CEO and Co-founder Verena Schöwel-Wolf.

MyoPax joined NOME in 2022.

Company details

Website

Myopax.com

More companies

MetsystemNOME2024-04-15T10:43:58+00:00

Metsystem
Metsystem

Digital Health
Droplet IVNOME2024-04-15T08:52:38+00:00

Droplet IV
Droplet IV

Medical Devices
Strike PharmaNOME2024-04-15T08:48:25+00:00

Strike Pharma
Strike Pharma

Therapeutics
InossiaNOME2024-04-15T08:43:52+00:00

Inossia
Inossia

Medical Devices
Linio BiotechNOME2024-04-15T08:37:31+00:00

Linio Biotech
Linio Biotech

Medical Devices
BrainCaptureNOME2024-04-15T08:32:40+00:00

BrainCapture
BrainCapture

Digital Health
2N PharmaNOME2024-04-15T08:22:22+00:00

2N Pharma
2N Pharma

Other, Therapeutics
One-Carbon TherapeuticsNOME2024-04-15T08:21:33+00:00

One-Carbon Therapeutics
One-Carbon Therapeutics

Other, Therapeutics

VIEW ALL PROJECTS

MyoPax

Project Description

MyoPax

Company details

Website

More companies